NH4Cl-induced contraction of porcine coronary artery involves activation of dihydropyridine-sensitive Ca2+ entry.
The role of voltage-dependent, dihydropyridine-sensitive Ca2+ channels in NH4Cl-induced vasoconstriction was investigated in isolated porcine coronary arteries by measuring in parallel isometric tone and 45Ca2+ uptake. NH4Cl (10-80 mM) concentration dependently induced tonic contractions which were preceded by a time lag of several minutes. Contractile responses to high (60 mM) as well as low (25 mM) concentrations of NH4Cl were markedly inhibited by 1 microM nifedipine or removal of extracellular Ca2+. The contractile effect of 25 mM NH4Cl was substantially enhanced by increasing extracellular K+ to 14.7 mM or by pretreatment of coronary arteries with either 5 mM tetraethylammonium chloride or 0.1 microM 1,4-dihydro- 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)-phenyl]-3-pyridine carboxylic acid methyl ester (BAY K8644). NH4Cl (60 mM) significantly increased 45Ca2+ uptake with a lag time of more than 5 min. The increase in 45Ca2+ uptake induced by 60 mM NH4Cl was abolished in the presence of 1 microM nifedipine. Although NH4Cl (25 mM) did not detectably stimulate 45Ca2+ uptake in normal K+ solution, it significantly augmented 45Ca2+ uptake when extracellular K+ was increased to 14.7 mM. Furthermore, NH4Cl (20 mM) potentiated histamine-induced contraction of coronary arteries. This potentiating effect of NH4Cl was completely antagonized by nifedipine. Our results suggest an involvement of nifedipine-sensitive Ca2+ channels in NH4Cl-induced vasoconstriction of porcine coronary artery.
Wakabayashi
I
I
Institut für Pharmakologie und Toxikologie, Universität Graz, Austria.
Kukovetz
W R
WR
Groschner
K
K
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000643:Ammonium Chloride / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002120:Calcium Channel Agonists / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects*; D003331:Coronary Vessels / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D009543:Nifedipine / Q000494:pharmacology*; D013552:Swine; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D014661:Vasoconstriction
D002120:Calcium Channel Agonists; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D013757:Tetraethylammonium Compounds; D000643:Ammonium Chloride; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D009543:Nifedipine; D002118:Calcium